GH Research (GHRS) Net Income towards Common Stockholders (2020 - 2026)

GH Research (GHRS) posted quarterly Net Income towards Common Stockholders of -$14.1 million for Q4 2025, down 60.61% year-over-year from -$35.9 million in Q4 2024, and down 0.83% quarter-over-quarter from -$14.0 million in Q3 2025.

GH Research (GHRS) Net Income towards Common Stockholders (2020 - 2026) Analysis & Trends

GH Research's Net Income towards Common Stockholders history runs 6 years deep, the most recent figure standing at -$14.1 million for Q4 2025.

  • In Q4 2025, Net Income towards Common Stockholders fell 60.61% year-over-year to -$14.1 million; the TTM figure through Dec 2025 stood at -$48.3 million (down 23.86% YoY), while the FY2025 annual figure was -$48.3 million, down 23.86% from the prior year.
  • Net Income towards Common Stockholders for Q4 2025 stood at -$14.1 million, down from -$14.0 million in the prior quarter.
  • The five-year high for Net Income towards Common Stockholders was $334000.0 in Q2 2022, with the low at -$16.6 million in Q4 2022.
  • The 5-year median for Net Income towards Common Stockholders is -$8.3 million (2023), against an average of -$7.7 million.
  • The sharpest annual moves came in 2021 and 2022: Net Income towards Common Stockholders slumped 2961.67% in 2021, then surged 115.72% in 2022.
  • GH Research's Net Income towards Common Stockholders stood at -$4.1 million in 2021, then slumped by 305.43% to -$16.6 million in 2022, then jumped by 32.04% to -$11.3 million in 2023, then advanced by 21.91% to -$8.8 million in 2024, then plunged by 60.61% to -$14.1 million in 2025.
  • Business Quant data shows GHRS's Net Income towards Common Stockholders at -$14.1 million in Q4 2025, -$14.0 million in Q3 2025, and -$9.3 million in Q2 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn 1.10 Bn
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn 1.30 Bn
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn 472.00 Mn
4 Revolution Medicines 43.64 Bn 43.64 Bn - -644.37 Mn
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn 237.01 Mn
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn 930.12
7 Royalty Pharma 33.72 Bn 35.84 Bn - 81.49 Mn
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn 164.49 Mn
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn -13.27 Mn
10 GH Research 2.02 Bn 1.68 Bn - -15.15 Mn

Historic Data

Download Data
DateValue
Jun 30, 2026 -15.15 Mn
Dec 31, 2025 -14.14 Mn
Sep 30, 2025 -14.02 Mn
Jun 30, 2025 -9.29 Mn
Mar 31, 2025 -10.81 Mn
Dec 31, 2024 -8.80 Mn
Sep 30, 2024 -12.11 Mn
Jun 30, 2024 -10.38 Mn
Mar 31, 2024 -7.67 Mn
Dec 31, 2023 -11.27 Mn
Sep 30, 2023 -5.65 Mn
Jun 30, 2023 -7.73 Mn
Mar 31, 2023 -10.94 Mn
Dec 31, 2022 -16.59 Mn
Sep 30, 2022 -441,000.00
Jun 30, 2022 334,000.00
Mar 31, 2022 -5.76 Mn
Dec 31, 2021 -4.09 Mn
Sep 30, 2021 -1.84 Mn
Jun 30, 2021 -2.13 Mn